TYRA Tyra Biosciences, Inc.
$22.03▼ -6.41%
Healthcare
Other
After hours
$22.27▲ +1.07%
Sep 11, 7:55 PM ET
Volume 1.55M
Avg Volume (10D) 1.41M
Key Metrics & Fundamentals
Market Cap
$1.31B
P/E Ratio
–
Div Yield
–%
52W Range
11.82 - 40.65
% vs 50 MA
-17.62%
% vs 200 MA
-22.57%
RSI-14
40.9
MACD Histogram
-0.0500
Beta (1Y vs SPY)
0.64
Free Cash Flow
-$31.14M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$48.87M
COGS
–
Operating Exp
$49.00M
Operating Income
-$49.00M
EBIT
-$49.00M
Pretax Income
-$45.56M
Net Income
-$45.56M
EPS (Diluted)
-0.69
Price & Volume History
Loading chart…
Recent News
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
Investor's Business Daily · Sep 9, 2026 8:54 PM
Tyra disappoints investors with bladder cancer data
BioPharma Dive · Sep 9, 2026 3:46 PM
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barrons.com · Sep 9, 2026 2:44 PM
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
InvestorsHub · Sep 9, 2026 2:05 PM
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
PR Newswire · Sep 9, 2026 11:00 AM
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
PR Newswire · Sep 8, 2026 8:05 PM
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
Stocktwits · Sep 4, 2026 6:25 PM
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
PR Newswire · Sep 4, 2026 12:00 PM
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
GlobeNewswire · Sep 1, 2026 12:30 PM
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
PR Newswire · Aug 4, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TYRA's money flow as a full page
Social Sentiment
No Reddit posts found for TYRA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.